Anap­tys­Bio touts PhI­II win in a rare form of pso­ri­a­sis. But it does­n't plan on keep­ing the drug

Anap­tys­Bio’s an­ti­body for a rare form of pso­ri­a­sis passed a Phase III study, but it’s still get­ting the boot, the com­pa­ny an­nounced on Mon­day.

Af­ter fail­ing pre­vi­ous tri­als in se­vere pal­mo­plan­tar pus­tu­lo­sis, ac­ne and hidradeni­tis sup­pu­ra­ti­va, Anap­tys­Bio an­nounced plans last year to out-li­cense its IL-36R-block­ing an­ti­body im­si­dolimab. How­ev­er, the can­di­date notched a win this week in gen­er­al­ized pus­tu­lar pso­ri­a­sis (GPP), an au­toin­flam­ma­to­ry dis­ease char­ac­ter­ized by sud­den flares of painful pus-filled blis­ters. Left un­treat­ed, flare-ups can al­so lead to life-threat­en­ing com­pli­ca­tions such as drops in blood pres­sure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER